How Your Immune System Ages and the Biomarkers That Reveal It

The global population aged 60 and over is projected to grow from 1.1 billion in 2023 to 2.1 billion by 2050, making immune aging one of the defining public health challenges of this century. This comprehensive review from Harvard- and Emory-affiliated researchers synthesizes the mechanistic underpinnings of immunosenescence, cataloging both cellular and molecular drivers of immune decline and their contributions to age-associated diseases including cardiovascular disease, neurodegeneration, cancer, and osteoarthritis.

At the cellular level, aging produces a paradoxical pattern in innate immunity: macrophages and dendritic cells increase numerically as a compensatory response, yet show significantly impaired phagocytic activity and diminished antigen presentation, ultimately compromising T cell priming. Neutrophil function also declines. The authors describe this as a 'quantitative-qualitative dissociation' — more cells, less capacity — that leaves older adults vulnerable despite apparent immune cellularity. This pattern likely reflects reactive hematopoietic expansion from senescent HSCs rather than true immune competence.

The adaptive immune system undergoes even more profound remodeling. Thymic involution progressively reduces naive T cell output, shifting the balance toward accumulated memory T cells with skewed T cell receptor (TCR) diversity. This contraction of TCR repertoire limits the ability to respond to novel antigens and reduces vaccine efficacy in older adults. B cell changes mirror this decline, with reduced repertoire diversity, impaired high-affinity antibody production, and defective long-lived plasma cell formation — contributing to heightened susceptibility to respiratory infections like influenza and pneumonia.

At the molecular level, senescence-associated secretory phenotype (SASP) components — including IL-6, IL-8, and TNF-α — are identified as central drivers of 'inflammaging,' a chronic low-grade inflammatory state. Single-cell RNA sequencing has enabled the discovery of key biomarkers: upregulation of cyclin-dependent kinase inhibitors CDKN1A (p21) and CDKN2A (p16INK4a) marks senescent immune cells. Epigenetic dysregulation compounds these effects, with EZH2-dependent H3K27me3 histone modifications and global DNA methylation shifts further orchestrating immune decline. Mitochondrial dysfunction, excessive ROS production, and impaired autophagy create additional layers of dysfunction.

The review catalogs a broad spectrum of interventional strategies organized into pharmacological, lifestyle, and cellular categories. Rapamycin (mTOR inhibition) enhances T cell function and improves vaccine responses. Senolytics like dasatinib plus quercetin selectively clear SASP-secreting senescent cells, reducing the inflammatory milieu. Metformin activates AMPK to reduce mitochondrial ROS. IL-7 therapy can restore thymic output and naive T cell pools. Lifestyle interventions — including caloric restriction, moderate exercise, and Mediterranean diet — show consistent benefits in reducing oxidative stress and maintaining thymic mass. Cellular strategies including FOXN1 gene therapy for thymic rejuvenation and microbiome modulation via probiotics or fecal transplant round out the therapeutic landscape, though most remain preclinical or in early trials.

The review's primary contribution is its integration of single-cell technologies with classical immunology to produce a comprehensive biomarker roadmap for immune aging. The authors emphasize that targeting these mechanisms — rather than treating downstream disease — represents the most promising frontier for extending healthspan. Limitations include the review's reliance on existing literature without original data, and the authors note no financial conflicts of interest.